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ABSTRACT
ObjeCtive
To create international symphysis-fundal height 
standards derived from pregnancies of healthy women 
with good maternal and perinatal outcomes.
Design
Prospective longitudinal observational study.
setting
Eight geographically diverse urban regions in Brazil, 
China, India, Italy, Kenya, Oman, United Kingdom, and 
United States.
PartiCiPants
Healthy, well nourished pregnant women enrolled into 
the Fetal Growth Longitudinal Study component of the 
INTERGROWTH-21st Project at 9-14 weeks’ gestation, 
and followed up until birth.
Main OutCOMe Measures
Symphysis-fundal height was measured every five weeks 
from 14 weeks’ gestation until birth using standardised 
methods and dedicated research staff who were blinded 
to the symphysis-fundal height measurements by 
turning the tape measure so that numbers were not 
visible during examination. The best fitting curve was 
selected using second degree fractional polynomials 
and further modelled in a multilevel framework to 
account for the longitudinal design of the study.
results
Of 13 108 women screened in the first trimester, 4607 
(35.1%) met the study entry criteria. Of the eligible 
women, 4321 (93.8%) had pregnancies without major 
complications and delivered live singletons without 
congenital malformations. The median number of 
symphysis-fundal height measurements was 5.0 
(range 1-7); 3976 (92.0%) women had four or more 
measurements. Symphysis-fundal height 
measurements increased almost linearly with 
gestational age; data were used to determine fitted 
3rd, 50th, and 97th centile curves, which showed 
excellent agreement with observed values.
COnClusiOns
This study presents international standards to 
measure symphysis-fundal height as a first level 
screening tool for fetal growth disturbances.
Introduction
Assessment of fetal growth is one of the aims of antena-
tal care, in order to identify small and large for gesta-
tional age fetuses at increased risk of perinatal 
morbidity and mortality. In low risk pregnancies, serial 
measurement of symphysis-fundal height (SFH) is rec-
ommended as a simple, inexpensive, first level, screen-
ing tool.1-3  Fetal growth in high risk pregnancies should 
be monitored with serial ultrasound scans by plotting 
anthropometric measures against international stan-
dards.4 In low and middle income countries, where 
access to ultrasound machines and trained ultrasonog-
raphers is limited, SFH measurement is often the 
screening tool of choice for fetal growth disturbances.
The sensitivity of SFH measurement to detect small 
for gestational age fetuses has been assessed in three 
systematic reviews.5-7  Observational cohort studies 
show wide ranges of sensitivity from 17% to 93%. There 
is also marked study heterogeneity mainly due to the 
variety of methods used, including varying thresholds 
for defining small for gestational age and the use of 
multiple SFH charts.5  In fact, we believe that at least 21 
different, locally derived SFH charts are currently being 
used in clinical practice worldwide.8-29
WhAT IS AlReAdy knoWn on ThIS TopIC
Symphysis-fundal height (SFH) measurement is routinely performed during 
antenatal care to screen for fetal growth disturbances
Three systematic reviews have assessed the sensitivity of SFH measurement to 
detect small for gestational age; observational cohort studies show wide ranges of 
sensitivity from 17% to 93%
It is likely that at least part of the reason for this wide range of sensitivities is that 
the methodology has never been standardised and a variety of different, locally 
derived SFH charts are currently in use
WhAT ThIS STudy AddS
This international study uses a prescriptive approach to develop international SFH 
standards using the eight urban populations of healthy, well nourished women in 
the INTERGROWTH-21st Project
These scientifically robust standards should be used as a first level screening tool 
to alert clinicians to disturbances in fetal growth, which should initiate referral for 
detailed assessment with ultrasound, if the resource is available
The charts complement unified tools for pregnancy assessment, including 
international standards for ultrasound dating of early pregnancy and assessment of 
fetal growth, maternal weight gain, newborn size for gestational age/sex, and 
preterm postnatal growth
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To improve the care offered to women worldwide, we 
have developed international SFH standards, which 
were derived from the same eight urban populations of 
healthy, well nourished women in the INTER-
GROWTH-21st Project. The project has already gener-
ated international standards for ultrasound dating of 
early pregnancy30  and assessment of fetal growth,4 
maternal weight gain,31  newborn size for gestational 
age and sex,32 33  and preterm postnatal growth.34
Methods
INTERGROWTH-21st was a multicentre, multiethnic, pop-
ulation based project, conducted between 2009 and 2014 
in eight countries.35  The project’s primary aim was to 
study growth, health, nutrition, and neurodevelopment 
from less than 14 weeks’ gestation to 2 years of age, using 
the same conceptual framework as the World Health 
Organization Multicentre Growth Reference Study.36
The details of population selection have been 
described elsewhere.35 37 In brief, all institutions provid-
ing obstetric care in eight urban areas in Brazil, China, 
India, Italy, Kenya, Oman, UK, and USA, with no or low 
levels of major, known, non-microbiological contami-
nation, were chosen as study sites. From these popula-
tions, healthy women with a naturally conceived 
singleton pregnancy, and who met the individual inclu-
sion criteria, were prospectively recruited into the Fetal 
Growth Longitudinal Study, one of the main compo-
nents of the INTERGROWTH-21st Project.
Gestational age was estimated on the basis of the last 
menstrual period provided that the date was certain, the 
woman had a regular 24-32 day menstrual cycle, she was 
not using hormonal contraception or breastfeeding in 
the preceding two months, and the estimated gestational 
age (based on the last menstrual period) agreed (within 
seven days) with a standardised measurement of fetal 
crown rump length at 9+0 to 13+6 weeks’ gestation.30 38 39 
Follow-up visits occurred every five weeks (within one 
week either side)—that is, possible ranges were 14-18, 
19-23, 24-28, 29-33, 34-38, and 39-42 weeks’ gestation.
At each visit, dedicated research staff who had under-
gone rigorous training and standardisation used the 
same protocols at all sites. Staff measured SFH first 
before taking fetal ultrasound measurements. With the 
woman in the supine position, having emptied her 
bladder, SFH was measured with a non-elastic metric 
tape (Chasmors) provided to all sites. After the start of 
the tape was positioned with one hand over the upper 
border of the symphysis pubis bone, the tape was 
placed in a straight line over the uterus until loss of 
resistance was felt when reaching the fundus. With the 
cubital edge of the hand used to sustain the tape in 
place at the point of the fundus, the tape was turned so 
that the numbers were visible to record the value to the 
nearest complete half centimetre.35
The process was then repeated to obtain a second 
measurement. Although it was not possible to blind the 
research staff to the gestational age at each visit, all SFH 
measurements were taken in a blinded fashion to reduce 
expected value bias by turning the tape measure so that 
no numbers were visible during the examination.
According to prespecified criteria, we excluded preg-
nancies complicated by fetal death or congenital abnor-
mality, catastrophic or severe medical conditions (such 
as cancer or HIV); those with severe unanticipated con-
ditions related to pregnancy that needed admission to 
hospital (such as eclampsia or severe pre-eclampsia); 
and those identified during the study who no longer ful-
filled the entry criteria (such as women who started 
smoking during pregnancy or had an episode of malaria).
statistical analysis
Sample size considerations are reported elsewhere.4 In 
keeping with the overall analysis strategy, our aim was 
to produce centiles that change smoothly with gesta-
tional age and maximise simplicity without compromis-
ing model fit.
The best fitting powers for the median SFH were pro-
vided by second degree fractional polynomials and fur-
ther modelled in a multilevel framework to account for the 
longitudinal study design. To obtain an equation for the 
standard deviation, we modelled the resulting variance 
components from the multilevel model that accounts for 
the correlations between and within participants using 
fractional polynomials. Goodness of fit was based on 
visual inspection of the overall model fit by comparing 
quantile-quantile (q-q) plots of the residuals, and the dis-
tribution of fitted Z scores across gestational ages.
Tables containing medians and standard deviations of 
the SFH  by gestational age, expressed in completed 
weeks  of gestation (as recommended by WHO Interna-
tional  Statistical Classification of Diseases and Related 
Health Problems, 10th revision), as well as printable charts, 
are freely available on the INTERGROWTH-21st website 
(https://intergrowth21.tghn.org; supplementary appendix).
For the analysis of estimation of gestational age as a 
function of SFH only, the problem of data truncation at 
the lower and upper gestational ages was overcome by 
use of the same approach applied to crown rump length 
data in the Fetal Growth Longitudinal Study.40 By use of 
the equation for SFH size according to gestational age 
(size chart), 40 observations for each day were simulated 
between 10+0 and 13+6 weeks’ gestation (n=1120). Simi-
larly, 40 observations for each day were simulated 
between 40+0 and 46+0 weeks’ gestation (n=1720)—that 
is, about the same number of observations for each day 
of gestational age in the untruncated dataset. After sim-
ulation, we restricted the data based on SFH by exclud-
ing actual and simulated values below 12 cm or above 
38 cm (because gestational age assessment based on SFH 
is not undertaken clinically beyond these limits) and visu-
ally inspecting a plot of the data to assess that the trunca-
tion problem had been overcome. This process resulted in 
a total of 814 simulated data being included in the final 
dataset. Using the augmented dataset, we conducted 
fractional polynomial regression analyses using the xrigls 
function in Stata (version 11.2) to model the mean and 
standard deviation for each biometric variable.40
Patient involvement
The steering committee of the project included a female 
lay adviser who had previously chaired an ethics 
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 committee; she contributed to the study design includ-
ing developing plans for participant recruitment and 
advice about the ethical conduct of the research.41
Results
Of 13 108 women screened in the first trimester, 4607 
women met the study entry criteria and were recruited 
across the eight study sites; their characteristics have 
been reported in detail previously.42  Of these women, 
4321 (93.8%) delivered live singletons without congeni-
tal malformations (fig 1), but 82 were excluded from the 
analysis because all SFH measures were missing (n=81) 
or a single measure was above 38 cm (n=1). In addition, 
we excluded 59 outlier observations (but not any 
women as a result), defined as SFH values greater than 
five standard deviations above the mean. Therefore, for 
the analysis of SFH for gestational age, 20 566 measure-
ments from 4239 women were used, which contained 
no simulated data.
For the estimation of gestational age from SFH, the 
dataset was augmented with simulated observations: 
1120 at the lower end and 1720 at the upper end. Subse-
quently, we excluded real and simulated SFH data 
below 12 cm (n=604 observations) and above 38 cm 
(n=1842 observations) to obtain the final analysis 
 sample of 20 837 observations. As a result, in the analy-
sis of gestational age for SFH, 814 were simulated and 
20 023 were measured data points in 4239 women 
(fig 1 ).  Baseline characteristics and perinatal events of 
the study population (n=4239, excluding simulated 
observations) are shown in table 1. The median number 
of SFH measurements in all women was 5.0 (range 1-7); 
3976 (92.0%) women had four or more measurements. 
Of 20 907 measurements, 18 061 (86.4%) were taken 
within the stipulated gestational age window, confirm-
ing strict adherence to the study protocol. As the rela-
tion between SFH and gestational age was almost 
linear, complex methods that allow for skewness and 
kurtosis were not required.
The relation between SFH and gestational age was 
best expressed by the equation: median SFH=5.133374 + 
0.1058353119 × (GA2) − 0.0231295 × (GA2) × ln (GA),  where 
GA is gestational age. The standard deviation of the SFH 
was expressed by: 
SD (SFH) = 0.9922667 + 0.0258087 × GA 
(where SD is standard deviation, SFH is in cm, GA is in 
exact weeks in decimals (eg, 36+0 and 36+1 weeks’ gesta-
tion are 36.0 and 36.14 weeks’ gestation, respectively), 
and ln is the natural logarithm).
Assessment of the goodness of fit—by comparing 
smoothed 3rd, 50th, and 97th centile curves and 
observed values—showed excellent agreement (fig 2). 
Overall, the mean differences between smoothed and 
observed centiles for the 3rd, 50th, and 97th centiles, 
were small: 0.28 cm (standard deviation 0.61), 0.04 cm 
(0.37), and 0.45 cm (0.51), respectively.
The equations for the median and standard deviation 
from the regression models allow calculations of any 
desired centiles according to gestational age in exact 
weeks. For example, centiles can be calculated as the 
mean plus or minus Z×standard deviation, where Z is 
−1.88, −1.645, −1.28, 0, 1.28, 1.645, and 1.88 for the 3rd, 
5th, 10th, 50th, 90th, 95th, and 97th centiles, respec-
tively. A computerised application for the use of these 
data for individuals and datasets will be made available 
(https://intergrowth21.tghn.org).
Number of women enrolled in the Fetal
Growth Longitudinal Study (n=4607)
Livebirths (n=4422)
Born alive without congenital malformation (n=4321)
Excluded (n=185):
  Lost to follow-up or withdrew consent (n=71)
  Severe maternal disorders (n=29)
  Smoking (n=6)
  Recreational drug use (n=1)
  Miscarriage, pregnancy termination, or stillbirth (n=78)
   
Livebirths with congenital malformation (n=101)
≥1 eligible measurement between 14-40 weeks
(n=4239 women)
Participants with no SFH measurements <38cm (n=82)
Fig 1 | Flowchart of recruitment of participants through the 
study. sFH=symphysis-fundal height
table 1 | baseline characteristics and perinatal events of study population (n=4239)
Characteristic Mean (standard deviation) no (%) of women
Maternal age (years) 28.4 (3.9) —
Maternal height (cm) 162.2 (5.8) —
Maternal weight (kg) 61.3 (9.1) —
Body mass index 23.3 (3.0) —
Gestational age at first visit (weeks) 11.8 (1.4) —
Nulliparous — 2907 (68.6)
Pre-eclampsia — 31 (<1)
Preterm birth (<37 weeks’ gestation) — 192 (4.5)
Term LBW <2500 g (≥37 weeks’ gestation) — 127 (3)
Male infant — 2106 (49.7)
Birth weight (≥37 weeks’ gestation; kg) 3.267 (0.444) —
Maternal baseline characteristics were measured at less than 14 weeks’ gestation. LBW=low birth weight.
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Fig 2 | scatterplot showing symphysis-fundal height (sFH) 
with gestational age. lines=fitted smoothed 3rd (bottom 
dashed line), 50th (middle solid line), and 97th (top 
dashed line) centile curves; open blue circles=empirical 
values for each week of gestation; grey circles=actual 
observations
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Table 2  and fig 3 present the international SFH stan-
dards for clinical use, and there is a printable chart 
available (supplementary appendix; can also be found 
at https://intergrowth21.tghn.org/ under “INTER-
GROWTH Standards & Tools”).
Estimation of gestational age from SFH was expressed 
by the equation: GA (exact weeks) = 6.585838 − 
2.7072585 × (SFH0.5) + 1.295291 × (SFH), where GA is ges-
tational age. Assessment of the goodness of fit showed 
excellent agreement; the equation can be used to esti-
mate gestational age in settings where more reliable 
information, such as ultrasound dating of the preg-
nancy, is not available (fig 4).
It is clear that SFH, as an indirect measure of the growth 
of the fetus and uterine volume, has limitations. Analysis 
of the duplicate SFH measurements obtained from all 
women showed that the 95% limits of agreement were 
about 1.5 cm (fig 5 ). Previous studies have demonstrated 
that interobserver agreement exceeds this value signifi-
cantly, with 95% limits of agreement of around 6 cm.43
All the clinical tools arising from the INTER-
GROWTH-21st Project, including the SFH charts, are 
freely available on our website for healthcare profes-
sionals and patients to use.
discussion
Principal findings
Based on the recommendations of the 1995 WHO Expert 
Committee regarding “the use and interpretation of 
anthropometry,”44 we selected a population based 
cohort of healthy, well nourished mothers at low risk of 
adverse outcomes to generate international standards 
describing optimal maternal, fetal, and newborn 
parameters. The SFH standards presented here are the 
fifth in the series to use the same conceptual approach 
and dataset derived from the mothers and babies who 
participated in the INTERGROWTH-21st Project.
table 2 | international symphysis-fundal height standards for clinical use, rounded to the 
nearest 0.5 cm
gestational 
age(exact weeks*)
no of sFH 
observations
Centiles of sFH (cm)
3rd 5th 10th 50th 90th 95th 97th
16 965 13.0 13.5 14.0 16.0 17.5 18.0 18.5
17 1140 14.0 14.5 15.0 17.0 18.5 19.0 19.5
18 872 15.0 15.5 16.0 18.0 19.5 20.0 20.5
19 508 16.0 16.5 17.0 19.0 20.5 21.0 21.5
20 747 17.0 17.5 18.0 20.0 21.5 22.0 22.5
21 872 18.0 18.0 19.0 21.0 22.5 23.5 23.5
22 991 19.0 19.0 20.0 22.0 24.0 24.5 24.5
23 960 20.0 20.0 20.5 23.0 25.0 25.5 25.5
24 618 20.5 21.0 21.5 24.0 26.0 26.5 27.0
25 702 21.5 22.0 22.5 24.5 27.0 27.5 28.0
26 836 22.5 23.0 23.5 25.5 28.0 28.5 29.0
27 934 23.5 24.0 24.5 26.5 29.0 29.5 30.0
28 939 24.5 25.0 25.5 27.5 30.0 30.5 31.0
29 724 25.5 26.0 26.5 28.5 31.0 31.5 32.0
30 744 26.5 26.5 27.5 29.5 32.0 32.5 33.0
31 772 27.0 27.5 28.0 30.5 33.0 33.5 34.0
32 927 28.0 28.5 29.0 31.5 34.0 34.5 35.0
33 964 29.0 29.5 30.0 32.5 34.5 35.5 36.0
34 747 29.5 30.0 31.0 33.0 35.5 36.5 36.5
35 760 30.5 31.0 31.5 34.0 36.5 37.0 37.5
36 714 31.5 31.5 32.5 35.0 37.5 38.0 38.5
37 1119 32.0 32.5 33.0 35.5 38.0 39.0 39.5
38 603 33.0 33.0 34.0 36.5 39.0 39.5 40.0
39 337 33.5 34.0 34.5 37.0 40.0 40.5 41.0
40 120 34.0 34.5 35.5 38.0 40.5 41.5 42.0
*That is, week plus 0 days.
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Fig 3 | international symphysis-fundal height (sFH) 
standards for clinical use. lines (from bottom to top)=3rd, 
10th, 50th, 90th, and 97th centiles. a printable chart is 
available in the supplementary appendix (can also be 
found at https://intergrowth21.tghn.org/ under 
“intergrOWtH standards & tools”)
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Fig 4 | gestational age as a function of symphysis-fundal 
height (sFH). lines=10th (bottom dashed line), 50th 
(middle solid line), and 90th (top dashed line) centiles; 
grey circles=actual observations; blue circles=simulated 
data to overcome truncation (see text for details)
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Fig 5 | bland altman plot of intraobserver variation of 
symphysis-fundal height (sFH) measurement; the central 
line shows the mean difference between observation 1 and 2 
(solid line, 0.07 cm) while the dashed lines show the 95% 
limits of agreement (upper dashed line 0.66cm, lower 
dashed line 0.81 cm)
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strengths and limitations of study
Although SFH measurement is a simple, inexpensive, first 
level screening tool in both high and low income settings, 
it is associated with a wide range of sensitivities for detect-
ing small for gestational age, principally because of the 
different measurement methods, charts, and thresholds 
used to perform an ultrasound scan. Another limitation of 
existing reference charts is that they use uncorroborated 
menstrual dates, which can cause artificial flattening of the 
growth curve at term, probably due to errors in dating that 
overestimate the length of gestation. The strict strategy for 
dating pregnancies based on the last menstrual period, 
corroborated by first trimester ultrasound in all women 
taking part in the INTERGROWTH-21st Project, shows no 
such flattening at term in the fetal growth standards.4
The standards we have developed overcome many of 
these methodological limitations. Their widespread 
implementation will allow clinical practice to be unified 
and comparisons to be made across international stud-
ies using a single chart derived from the same low risk 
population as the other INTERGROWTH-21st standards. 
One possible limitation of our study is that the measure-
ments were obtained under near optimal conditions—all 
the dedicated staff taking the measurements were well 
trained, used the same protocol under blinded condi-
tions, and had no time restrictions to complete the 
examinations. Consequently, the intraobserver variabil-
ity in the measurements was probably better than that 
reported previously. Under less than ideal conditions, 
the measures obtained might also have been different. 
However, our actual aim was to report measures under 
optimal conditions so that they can serve as a standard.
These international, prescriptive standards, which 
describe optimal growth, have the potential to improve 
pregnancy outcomes by reducing the risk of failure to 
recognise a fetus of small for gestational age through 
the use of locally produced reference charts that include 
data derived from high risk mothers.
Comparison with other studies
The introduction of these international standards should 
be relatively simple because the practice of SFH mea-
surement is so well established in both developed and 
developing countries. In the UK, for example, the 
National Institute for Health and Care Excellence45  rec-
ommends serial measurement of SFH at each antenatal 
appointment from 24 weeks’ gestation. In a 2011 system-
atic review, Imdad and colleagues6 concluded that detec-
tion and management of intrauterine growth restriction 
(IUGR) using maternal body mass index screening, SFH 
measurement, and targeted ultrasound followed by 
appropriate management could be an effective method of 
reducing IUGR related stillbirths. This finding remains to 
be proven in a clinical trial. In general, referral from first 
level SFH screening to more detailed assessment is 
 warranted if SFH measures are below or above a certain 
centile, provided that the estimation of gestational age is 
accurate, or if repeat measures show a drop or accelera-
tion across centiles. We have made such implementation 
easier by posting freely available, printable SFH charts 
on our website for plotting the measures.
It would not be appropriate for us, however, to make 
recommendations about the cutoff values that warrant 
referral. In general, first level screening tests for anthro-
pometric measures use a relatively high screen positive 
rate (usually cutoff values at the 10th and 90th centiles) 
in order to maximise sensitivity. Considering that the 
action taken for false positives is non-invasive (that is, 
closer surveillance), this might be acceptable. However, 
in service deprived areas with high rates of IUGR, such 
cutoff values could produce an unmanageable number 
of referrals and should be adapted.
What we can say is that the use of international, pre-
scriptive standards, which describe optimal growth, 
instead of a wide range of locally derived reference 
charts, should reduce the risk of failing to diagnose 
both restricted and excessive fetal growth and will facil-
itate comparisons across populations.
Conclusions and policy implications
Assessment of fetal size and growth by SFH measure-
ment is a simple and inexpensive clinical activity, 
widely used during antenatal care in both high and low 
income settings. The international standards we pres-
ent will go some way to reducing the wide range in sen-
sitivity for the detection of small for gestational age. 
Given that SFH measurement constitutes a first level 
screen, with suspected pregnancies referred—without 
treatment—for further non-invasive investigations with 
ultrasound, a high false positive rate could be accept-
able if it leads to improved detection rates overall. 
Future work should concentrate on the optimal fre-
quency of SFH measurement to maximise detection.
Assessment of fetal growth using SFH remains an 
important first level screening tool during routine ante-
natal care. We recommend the use of the new interna-
tional SFH standards in combination with standardised 
measurement methodology to unify and improve clini-
cal practice. Plotting measurements in the medical 
records with these tools should be undertaken to iden-
tify women who require referral for an ultrasound scan.
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